上海宣泰医药科技股份有限公司 2025 年限制性股票激励计划实施管理办法（修订稿） 为保证上海宣泰医药科技股份有限公司（以下简称"公司"）2025 年限制性股票 激励计划（以下简称"本计划"）的顺利进行，进一步完善公司法人治理结构，形成 良好均衡的价值分配体系，充分调动公司中高层管理人员以及核心骨干人员的工作 积极性，促进公司业绩稳步提升，确保公司发展战略和经营目标的实现，根据国家 有关规定和公司实际情况，特制定本办法。 一、管理机构 （一）股东会作为公司的最高权力机构，负责审议批准本计划的实施、变更 和终止。股东会可以在其权限范围内将与本计划相关的全部或部分事宜授权董事 会办理。 （二）董事会是本激励计划的执行管理机构，负责本激励计划的实施。董事 会下设薪酬与考核委员会，负责拟订和修订本激励计划并报董事会审议，董事会 对激励计划审议通过后，报股东会审议。董事会可以在股东会授权范围内办理本 激励计划的其他相关事宜。 （三）薪酬与考核委员会是本计划的监督机构，负责审核激励对象的名单， 就本计划是否有利于公司的持续发展，是否存在明显损害公司及全体股东利益的 情形发表意见，对本计划的实施是否符合相关法律、行政法规、 ...

1、公司不存在《管理办法》等法律、法规规定的禁止实施限制性股票激励 计划的情形，包括： （1）最近一个会计年度财务会计报告被注册会计师出具否定意见或者无法 表示意见的审计报告； （2）最近一个会计年度财务报告内部控制被注册会计师出具否定意见或无 法表示意见的审计报告； 上海宣泰医药科技股份有限公司 董事会薪酬与考核委员会关于公司《2025 年限制性股票激励 计划（草案修订稿）》及其摘要的核查意见 上海宣泰医药科技股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《国有控股上市公司（境内）实施股权激励试行办法》（国资发分配 〔2006〕175 号）、《关于规范国有控股上市公司实施股权激励制度有关问题的通 知》（国资发分配〔2008〕171 号）、《关于本市国有控股上市公司推进股权激励 工作促进高质量发展的指导意见》（沪国资委分配〔2019〕303 号）、《上海证券 交易所科创板股票上市规则》（以下简称"《上市规则》"）、《科创板上市公司自 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2026-004 上海宣泰医药科技股份有限公司 第二届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鉴于上述修订，公司第二届董事会第二十二次会议审议通过的《关于公司 <2025 年限制性股票激励计划（草案）>及其摘要的议案》将不再提交公司股东 会审议。本议案需提交公司股东会审议。 1 / 2 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的 《2025 年限制性股票激励计划（草案修订稿）》和《2025 年限制性股票激励计 划（草案修订稿）摘要公告》（公告编号：2026-003）。 一、董事会会议召开情况 上海宣泰医药科技股份有限公司（以下简称"公司"）第二届董事会第二十 三次会议于 2026 年 1 月 14 日以现场与通讯相结合的方式召开。本次会议通知于 2026 年 1 月 9 日以邮件形式发送。本次会议应出席董事 8 人，实际出席董事 8 人，会议由董事长叶峻先生主持。会议的召集和召开程序符合《中华人民 ...

Group 1 - The company has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is indicated for the treatment of invasive aspergillosis and mucormycosis in adult patients [1][4] - The original product was developed by Pfizer and was approved for marketing in China in June 2022, subsequently included in the Class B medical insurance catalog, leading to rapid market growth [1][2] - According to sales data from MoSheng Pharmaceuticals, the projected sales for the product are RMB 204 million for the year 2024 and RMB 172 million for the first half of 2025 [1] Group 2 - The approval of injectable isavuconazole is expected to enrich the company's product line and enhance its competitiveness, positively impacting future operating performance [2] - However, the specific sales performance may be influenced by various factors such as market conditions and channel expansion, introducing a degree of uncertainty [2]

Core Viewpoint - Xuantai Pharmaceutical (688247) has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is expected to enhance the company's product line and competitiveness, positively impacting future operating performance [1] Group 1 - The company announced the approval of injectable isavuconazole on January 6 [1] - The approval is seen as a strategic move to enrich the company's product offerings [1] - The introduction of this product is anticipated to have a positive effect on the company's future financial performance [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）收到国家药品 监督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，批准公司 注射用硫酸艾沙康唑上市。现将相关情况公告如下： 一、药品基本情况 二、药品的其他相关情况 注射用硫酸艾沙康唑适用于治疗成人患者下列感染：侵袭性曲霉病，侵袭性 毛霉病。 证券代码：688247 证券简称：宣泰医药 公告编号：2026-001 上海宣泰医药科技股份有限公司自愿披露 关于注射用硫酸艾沙康唑获得国家药品监督管理局 批准的公告 2026 年 1 月 7 日 注射用硫酸艾沙康唑原研产品为辉瑞公司开发，于 2022 年 6 月在国内获批 上市，同年谈判纳入医保乙类品种目录，随后迎来医院市场快速放量。根据摩熵 医药销售数据，该产品 2024 年年度及 2025 年上半年度销售额分别为人民币 2.04 亿元、1.72 亿元。 三、对公司的影响及风险提示 本次注射用硫酸艾沙康唑获得国家药监局批准上市，有利于进一步丰富公司 的产品线，提升公司 ...

Core Viewpoint - XuanTai Pharmaceutical (688247) has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients [1] Group 1 - The company announced the receipt of the drug registration certificate on January 6 [1] - Injectable isavuconazole is specifically approved for treating two serious fungal infections: invasive aspergillosis and invasive mucormycosis [1]

Core Viewpoint - The company, Xuantai Pharmaceutical (688247.SH), has received approval from the National Medical Products Administration (NMPA) for the marketing of its injectable Isavuconazole sulfate, which is indicated for the treatment of invasive fungal infections in adult patients [1] Group 1 - The injectable Isavuconazole sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing of injectable Isavuconazole, which is expected to enhance its product line and competitiveness, although sales performance remains uncertain [1] Group 1: Product Approval - The company announced the approval of injectable Isavuconazole with the registration number H20256410, in a specification of 0.2g [1] - This drug is indicated for the treatment of adult invasive aspergillosis and invasive mucormycosis [1] Group 2: Market Potential - The original product is projected to generate sales of 204 million yuan in 2024 and 172 million yuan in the first half of 2025 [1] - The approval is expected to enrich the company's product portfolio and enhance its competitive position in the market [1]

Core Viewpoint - The company, Xuantai Pharmaceutical (688247.SH), has received approval from the National Medical Products Administration (NMPA) for the marketing of its injectable Isavuconazole sulfate, which is indicated for the treatment of invasive fungal infections in adult patients [1] Group 1 - The injectable Isavuconazole sulfate is approved for the treatment of invasive aspergillosis and invasive mucormycosis [1]